Ann: Lumos Investor Roadshow Presentation, page-53

Thanks for the information from the session.

Good to hear about the broker discussions too rather than just an info session to clarify concerns. Hopefully we see some substantial consistent volume in the stock to see this return to reasonable levels. ViraDX is probably not a huge loss in the scheme of things as it is purely a seasonal product. Outside of winter, it wouldn't be used. Febridx would be a all year product. Efforts on that would be ideal.

The target would be the services side and reoccurring income from febridx sales and manufacturing of devices for the readers people use etc. Its clearly where the money is and has been for Lumos.